• INSTRUCTIONS FOR AUTHORS
  • SUBSCRIBE
  • CALL FOR PAPERS
  • JOIN PEER REVIEW
  • PERMISSIONS REQUESTS
  • ABOUT US
  • CONTACT US
  • HOME
  • CURRENT ISSUE
  • PAST ISSUES
  • ONLINE ONLY
  • SUPPLEMENTS
  • CONTINUING EDUCATION
  • EDITORIAL BOARD
  • ANNUAL INDEX

FEATURES

Impact of Treatment by NCQA-Certified Physicians on Diabetes-Related Outcomes

Brett Pinsky, MPH
; James Harnett, PharmD
; Ryne Paulose-Ram, PhD
; Jack Mardekian, PhD
; Navendu Samant, PhD
; Kavita V. Nair, PhD
Stakeholder Perspective by Walid F. Gellad, MD, MPH

Are ACOs the Answer to High-Value Healthcare?

Wing Yeung, MA
; Harrison Burns, III, BS, PAHM
; Deryk Loiacono, PharmD
Stakeholder Perspective by F. Randy Vogenberg, RPh, PhD

Sensitivity of Medication Use to Formulary Controls in Medicare Beneficiaries: A Review of the Literature

Rahul Shenolikar, PhD
; Amanda Schofield Bruno, PhD, MPH
; Michael Eaddy, PharmD, PhD
; Christopher Cantrell, PhD
Stakeholder Perspective by Gary M. Owens, MD

Introduction

In Search of Stakeholder Collaboration to Stem the Cardiometabolic Epidemic

Dalia Buffery, MA, ABD

Original Research

Obesity in the Workplace: Impact on Cardiovascular Disease, Cost, and Utilization of Care

Alberto M. Colombi, MD, MPH; G. Craig Wood, MS
Stakeholder Perspective by Wayne M. Lednar, MD, PhD

Clinical

A Call to Action: Responding to the Future Forecasting of Cardiovascular Disease in America

Robert Lee Page ii, PharmD, MSPH, FAHA, FCCP, FASCcP, FASHP, BCPS; Vahram Ghushchyan, PhD; Kavita Nair, PhD
Stakeholder Perspective by James T. Kenney, RPh, MBA

Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring, and Healthcare Implications

Henry J. Riordan, PhD; Paola Antonini, MD, PhD; Michael F. Murphy, MD, PhD
Stakeholder Perspective by Atheer A. Kaddis, PharmD

Current Therapies and Emerging Drugs in the Pipeline for Type 2 Diabetes

Quang T. Nguyen, DO; Karmella T. Thomas, BS, RD; Katie B. Lyons, MS II; Loida D. Nguyen, PharmD, BCBS; Raymond A. Plodkowski, MD
Stakeholder Perspective by James V. Felicetta, MD

Lipid Management in Patients with Type 2 Diabetes

Marsha J. Daniel, PharmD, cPh, CDE
Stakeholder Perspective by Gary M. Owens, MD

Current Issue


Industry Trends

Back to School: Quality Improvement through Academic Detailing

Barry Patel, PharmD

Drug Shortages the “New” Old Problem: People Are (Finally) Talking

Caroline Helwick

ONLINE ONLY

Introducing THE LYNX GROUP™: A Global, Strategic Alliance Providing Pivotal and Contemporary Medical Information and Education for All Stakeholders in Healthcare
more

ADA Highlights 2011

ADA President’s Views on Clinical Management of Type 2 Diabetes
Ultra-Long-Acting Insulin Degludec Noninferior to Insulin Glargine with Less Hypoglycemia in Type 1 and Type 2 Diabetes
Type 2 Diabetes Treatment in Patients with CKD Should Conform to NKF Guidelines for Better Outcomes, Lower Costs
More ADA 2011 Highlight

Search

e-Newsletter

 
 


Close

Poll

Should everyone be required to purchase health insurance?:

Continuing Education (CE)

Optimizing New and Emerging Therapies for Treatment and Symptom Management of Multiple Sclerosis in Managed Care
Evolving Role of Biologics: A Payer’s and Provider’s Perspective
more

Supplements

The Taxanes for Metastatic Breast Cancer: Total Cost of Care Considerations
Tradjenta™ (linagliptin) Tablets A New Type 2 Diabetes Treatment Option for Adult Patients with Inadequate Glycemic Control: Clinical Trials Review, Part 3
more
Terms of Use • Copyright © 2010-2011 Engage Healthcare Communications, LLC. All rights reserved. • Privacy Policy